EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics
Published on 08/07/2025 at 18:05 | prnewswire.co.uk
Proceeds will fund clinical development of oncology and immunology therapeutics derived from innovative antibody payload platform Mark Throsby, industry veteran and former CSO of Merus, joins as Executive ChairView original content:https://www.prnewswire.co.uk/news-releases/eqt-life-sciences-leads-54-million-series-a-financing-of-atb-therapeutics-302308732.html
en | boerse | 67976018 |
